Ironwood Pharma (IRWD), Astellas Announce Linaclotide Phase 3 Met Primary Endpoint in IBS-C
Tweet Send to a Friend
Astellas Pharma and Ironwood Pharma (NASDAQ: IRWD) announced that the Phase III clinical trial of linaclotide conducted in Japan in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE